INBS heads into mid-May with a sharp divergence between price momentum and short-side positioning — the stock is up 31% on the week, but short sellers have simultaneously doubled down.
The most striking data point is not the rally. It is the speed with which short interest has rebuilt alongside it. Estimated short interest doubled over the past month, rising 99% to 74,548 shares. On a weekly basis alone it jumped 43%. At 3.6% of the free float, the absolute level is not extreme for a micro-cap, but the pace of accumulation while the stock was climbing hard is notable. This is not short sellers covering into a move — they are adding into one.
The borrow market reinforces how contested this stock is. Cost to borrow is running at 212%, a level that has been broadly sticky for the past six weeks — it touched 247% in early April and has ranged between 191% and 235% ever since. At 212%, lenders are extracting a steep annualised premium from anyone maintaining a short position through this rally. Availability is at 94% of current short interest, which means the lending pool is moderately tight but not yet under acute squeeze pressure; the 52-week high for borrowing stress on this name saw availability effectively collapse to zero, so the current setup leaves room for the borrow market to tighten further. The ORTEX short score has climbed to 64.9 over the past two weeks, up from 58.9 in late April, confirming the incremental build in short-side pressure.
The earnings backdrop adds another layer of complexity. Intelligent Bio's most recent print — on May 8 — produced a 37% single-day jump, which accounts for a sizeable chunk of the weekly gain. Prior to that event, the three preceding earnings releases each produced negative one-day returns averaging around 3%, with five-day follow-throughs consistently in the red. The May 8 move breaks that losing streak decisively. Next confirmed earnings are flagged for August 19, leaving more than three months before the next scheduled catalyst.
Ownership is extremely thin. The holder list is dominated by a handful of names — two individuals together hold roughly 3.2% — with institutional presence near-absent. The Vanguard Group holds under 0.5% and Geode Capital Management less than 0.3%. For a stock with a market cap below $7 million, that concentration means a relatively small number of participants can move the tape sharply in either direction. Insider data in the snapshot is stale, last updated in late 2023, so the picture of management behaviour at current price levels is opaque.
The setup here is one to watch for tension between two forces: a fresh post-earnings momentum bid and a short base that has been rebuilt aggressively into the move, at a cost-to-borrow level that makes holding shorts expensive to sustain.
See the live data behind this article on ORTEX.
Open INBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
